Skip to main content

HeartBeam, Inc 10-Q for FY2026 Q3

HeartBeam, Inc. (BEAT)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

HeartBeam, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$3.01M
compared with a net loss of $5.26M a year earlier
Diluted EPS
-$0.05
compared with -$0.15 a year earlier